Artivion (AORT) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Company overview and strategic focus

• Focused on aortic disease, with $392M revenue guidance and $70M EBITDA for the year.

• Core products include allograft and mechanical aortic valves, stent grafts, and BioGlue surgical sealant.

• Transformation from a diversified portfolio to a focused aortic company through divestitures and acquisitions.

• Leadership team with deep cardiovascular and stent graft experience, led by a decade-long CEO.

• Strategic goal to sustain double-digit revenue growth and grow EBITDA at twice the revenue rate.

Product portfolio and differentiation

• Only decellularized pulmonary valve on the market, used in the Ross procedure, with leading market share.

• On-X mechanical heart valve allows for lower blood thinner dosage, reducing major bleeding by 85%.

• BioGlue is the only sealant indicated for acute Type A dissections, supporting stable, defendable growth.

• Products are highly differentiated and face limited new competition due to market size and regulatory barriers.

Stent graft business and pipeline

• Advanced stent grafts drive most revenue, focusing on complex aortic segments with high growth and margins.

• AMDS device for acute Type A dissections shows 72% mortality improvement; U.S. approval targeted for H2 2025.

• NEXUS device for chronic dissections/aneurysms in clinical trial, with U.S. launch expected in Q4 2026.

• Robust pipeline of $100M-$200M opportunities, with new launches expected almost annually.